Zimbabwe has declined a major US healthcare agreement worth $367m (272 million pounds) spanning five years due to the United States' insistence on confidential biological samples.
The decision was revealed following a government memo dated December was leaked, revealing that President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesman later clarified that the US was requesting biological samples for research and profit but was unwilling to guarantee the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further negotiations to secure a agreement agreeable to all parties so the country's critical HIV programme can continue.
Broader Context
This development follows a similar case in neighbouring Kenya, where a court blocked a related health funding agreement following concerns were raised about the security of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance openness and responsibility.
As per statements, 16 African countries have to date signed similar health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded initiatives," Tremont commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to share its biological resources and data for a long time, without any corresponding guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for scientific discovery with no certainty that the resulting innovations would be available to our people if a new disease outbreak arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining frameworks previously established via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to manage future global health emergencies.
"This framework is designed to guarantee that when a nation provides its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our American counterparts on how future co-operation could be structured in a way that honours the sovereignty and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but suggested that talks need to persist given that a large portion of the nation's Aids initiatives were funded by external financing.
"If specific concerns arise, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," the group commented.
This impasse highlights the complex challenges between accepting much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.